Nepafenac — Membership Pricing
Nepafenac is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Nepafenac Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $172.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Nepafenac
Nepafenac is a prescription medication. Ask your doctor if Nepafenac is right for you.
How to Check Nepafenac Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Nepafenac at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Eye & Vision
About Nepafenac
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) prescribed as eye drops to reduce pain and inflammation following cataract surgery and other eye procedures. Like many specialty medications, nepafenac can be expensive—but TheDrugClub members enjoy $0 co-pays on this essential medication with convenient free home delivery.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Nepafenac is approved for (FDA label)
ILEVRO ® 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery. ILEVRO ® 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery ( 1 ).
Source: Read the full FDA label on DailyMed. Label effective date: April 1, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Nepafenac (FDA label)
Sterile ophthalmic suspension 0.3%: 1.7 mL in a 4 mL bottle and 3 mL in a 4 mL bottle. Sterile ophthalmic suspension 0.3%: 3 mL in a 4 mL bottle. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 10f411d3-a81e-074a-e063-6294a90ab547. SPL document ID: 4e6f184f-0de5-acca-e063-6394a90ac321. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Nepafenac (FDA label)
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice. Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Harrow Eye, LLC at 1-833-4HARROW or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Serious and Otherwise Important Adverse Reactions The following adverse reactions are discussed in greater detail in other sections of labeling.
Source: FDA prescribing information (DailyMed). Set ID: 10f411d3-a81e-074a-e063-6294a90ab547. SPL document ID: 4e6f184f-0de5-acca-e063-6394a90ac321. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Nepafenac (FDA label)
ILEVRO ® 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs). Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS). ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 10f411d3-a81e-074a-e063-6294a90ab547. SPL document ID: 4e6f184f-0de5-acca-e063-6394a90ac321. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Warnings and precautions for Nepafenac (FDA label)
Increased bleeding time due to interference with thrombocyte aggregation ( 5.1 ) Delayed healing ( 5.2 ) Corneal effects including keratitis ( 5.3 ) 5.1 Increased Bleeding Time With some NSAIDs including ILEVRO ® 0.3%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery. It is recommended that ILEVRO ® 0.3% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. 5.2 Delayed Healing Topical NSAIDs including ILEVRO ® 0.3%, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing.
Source: FDA prescribing information (DailyMed). Set ID: 10f411d3-a81e-074a-e063-6294a90ab547. SPL document ID: 4e6f184f-0de5-acca-e063-6394a90ac321. Label effective date: April 1, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.